Haringman J J, Tak P P
Academisch Medisch Centrum/Universiteit van Amsterdam, afd. Klinische Immunologie en Reumatologie, F4-218, Meibergdreef 9, 1105 AZ Amsterdam.
Ned Tijdschr Geneeskd. 2004 Sep 4;148(36):1760-4.
Chemokines form a relatively new family of chemotactic cytokines that seem to play a central role in the migration and activation of leukocytes in a wide variety of immune-mediated disorders. Specific therapy targeted against these proteins may well become an effective treatment in many of these disorders. The efficacy and safety of chemokine blockade is currently being investigated in clinical trials on patients with HIV infection, multiple sclerosis, rheumatoid arthritis and other chronic inflammatory disorders. The first results have been reported in patients with rheumatoid arthritis and these seem to confirm the potency of this treatment.
趋化因子构成了一个相对较新的趋化性细胞因子家族,它们似乎在多种免疫介导疾病中白细胞的迁移和激活过程中发挥核心作用。针对这些蛋白质的特异性疗法很可能会成为许多此类疾病的有效治疗方法。目前,在针对感染HIV、患有多发性硬化症、类风湿性关节炎及其他慢性炎症性疾病的患者进行的临床试验中,正在研究趋化因子阻断的疗效和安全性。类风湿性关节炎患者的首批结果已被报道,这些结果似乎证实了这种治疗方法的有效性。